[Correlations between OCT4 expression and clinicopathological factors and prognosis of patients with lung adenocarcinoma]

OCT4表达与肺腺癌患者临床病理因素及预后的关系

阅读:6
作者:Xueyan Zhang, Huimin Wang, Bo Jin, Qianggang Dong, Jinsu Huang, Baohui Han

Background

In recent years, cases of lung adenocarcinoma morbidity have consistently grown. OCT4 is the key gene that controls the automatic renewal of stem cells, and regulates the proliferation and differentiation of cancer stem cells. The

Conclusions

OCT4 expression is related to metastasis and chemoresistance in lung adenocarcinoma patients, and thus indicates poor prognosis. 背景与目的 肺腺癌发病率不断升高,而OCT4是调控干细胞自我更新的关键基因,在癌干细胞的增殖分化过程中起重要调节作用。本研究目的为检测肺腺癌组织中OCT4表达,并分析其与肺腺癌患者转移、化疗疗效及预后的相关性。 方法 采用免疫荧光方法检测肺腺癌组织OCT4表达。卡方检验OCT4表达与临床病理指标的关系,Kaplan-Meier生存曲线计算生存率,采用Cox分析评估各指标与患者生存之间的关系。结果 126例肺腺癌组织中,91例可观察到OCT4阳性细胞。OCT4表达与肺腺癌患者转移及化疗耐药密切相关,且与患者无病生存期和生存期呈明显负相关。结论 OCT4表达与肺腺癌患者的转移及化疗耐药相关,提示预后不良。

Methods

Immunofluorescence method was employed to detect OCT4 expression in lung adenocarcinoma tissues. The relationship between OCT4 expression and clinical pathological indicators is examined through chi-square test. Moreover, the survival rate is calculated through the Kaplan-Meier survivorship curve. Finally, the relevance between the indicators and patient survival is estimated using Cox analysis.

Results

Among the 126 tissue samples of lung adenocarcinoma, 91 showed OCT4 positive cells. OCT4 expression is closely related to metastasis and chemoresistance in lung adenocarcinoma patients, and negatively corresponds to the patients' disease-free survival and survival periods. Conclusions: OCT4 expression is related to metastasis and chemoresistance in lung adenocarcinoma patients, and thus indicates poor prognosis. 背景与目的 肺腺癌发病率不断升高,而OCT4是调控干细胞自我更新的关键基因,在癌干细胞的增殖分化过程中起重要调节作用。本研究目的为检测肺腺癌组织中OCT4表达,并分析其与肺腺癌患者转移、化疗疗效及预后的相关性。 方法 采用免疫荧光方法检测肺腺癌组织OCT4表达。卡方检验OCT4表达与临床病理指标的关系,Kaplan-Meier生存曲线计算生存率,采用Cox分析评估各指标与患者生存之间的关系。结果 126例肺腺癌组织中,91例可观察到OCT4阳性细胞。OCT4表达与肺腺癌患者转移及化疗耐药密切相关,且与患者无病生存期和生存期呈明显负相关。结论 OCT4表达与肺腺癌患者的转移及化疗耐药相关,提示预后不良。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。